The Danger of Substandard Drugs in Emerging Markets: An Assessment of Basic Product Quality

Pharmacologia 3(2):46-51, March 2012

6 Pages Posted: 19 Oct 2013

See all articles by Roger Bate

Roger Bate

American Enterprise Institute (AEI)

Lorraine Mooney

Africa Fighting Malaria (UK)

Julissa Milligan

American Enterprise Institute (AEI)

Date Written: June 28, 2011

Abstract

Background: Increasing competition generally decreases product prices, but in the case of pharmaceuticals, this is only beneficial if competitor products are therapeutically equivalent. This study analyzed drug samples from countries with emerging economies, assessing them for basic quality.

Results: Removing all obvious and suspected counterfeit products and degraded products, 1912 samples remained. 3.8% failed basic quality control tests performed with the Global Pharma Health Fund e.V. Minilab. 5.2% failed product authentication by raman spectrometer. Africa has a greater problem with substandard products than any other location.

Conclusions: Since all of the sampled drugs are used to treat potentially lethal infections, it is important that the threat of these substandard products be more widely recognized.

Suggested Citation

Bate, Roger and Mooney, Lorraine and Milligan, Julissa, The Danger of Substandard Drugs in Emerging Markets: An Assessment of Basic Product Quality (June 28, 2011). Pharmacologia 3(2):46-51, March 2012, Available at SSRN: https://ssrn.com/abstract=2341927

Roger Bate (Contact Author)

American Enterprise Institute (AEI) ( email )

1150 17th Street, N.W.
Washington, DC 20036
United States

Lorraine Mooney

Africa Fighting Malaria (UK) ( email )

Cambridge
United Kingdom

Julissa Milligan

American Enterprise Institute (AEI) ( email )

1150 17th Street, N.W.
Washington, DC 20036
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
81
Abstract Views
504
rank
329,568
PlumX Metrics